Physician profile
Ashwin Ashok
NPI 1134311236
$3,574.68
in general payments reported to CMS, 2019-2025
18 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.24 · 2022: $112 · 2023: $417 · 2024: $1,329 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,322 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.04 |
| Education | $117.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,095.85 | 2023-2025 | Rinvoq, Skyrizi |
| Phathom Pharmaceuticals, INC. | $465.46 | 2024-2025 | Voquezna |
| Genzyme Corporation | $427.02 | 2023-2025 | |
| Ardelyx, INC. | $313.06 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $221.77 | 2022-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $176.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2024 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $145.73 | 2023-2024 | Eohilia, Gattex, Entyvio |
| Regeneron Healthcare Solutions, INC. | $143.55 | 2022-2023 | Dupixent |
| Celltrion USA INC. | $121.62 | 2023-2025 | Zymfentra, Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.67 | 2022-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $43.25 | 2025 | Enhertu |
| Celgene Corporation | $40.10 | 2023 | Zeposia |
| Novo Nordisk INC | $36.04 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $28.47 | 2023 | Rebyota |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $23.97 | 2025 | Sutab, Suflave |
| Boston Scientific Corporation | $23.24 | 2021 | |
| Endogastric Solutions, INC | $19.40 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Ashok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.